nach oben

CNS Drugs

Erschienen in:

01.12.2002 | Review Article

Non-Cholinergic Strategies for Treating and Preventing Alzheimer’s Disease

verfasst von: Dr P. Murali Doraiswamy

Erschienen in: CNS Drugs | Ausgabe 12/2002

Einloggen, um Zugang zu erhalten

Abstract

The pathophysiology of Alzheimer’s disease is complex and involves several different biochemical pathways. These include defective β-amyloid (Aβ) protein metabolism, abnormalities of glutamatergic, adrenergic, serotonergic and dopaminergic neurotransmission, and the potential involvement of inflammatory, oxidative and hormonal pathways. Consequently, these pathways are all potential targets for Alzheimer’s disease treatment and prevention strategies. Currently, the mainstay treatments for Alzheimer’s disease are the cholinesterase inhibitors, which increase the availability of acetylcholine at cholinergic synapses. Since the cholinesterase inhibitors confer only modest benefits, additional non-cholinergic Alzheimer’s disease therapies are urgently needed.

Several non-cholinergic agents are currently under development for the treatment and/or prevention of Alzheimer’s disease. These include anti-amyloid strategies (e.g. immunisation, aggregation inhibitors, secretase inhibitors), transition metal chelators (e.g. clioquinol), growth factors, hormones (e.g. estradiol), herbs (e.g. Ginkgo biloba), nonsteroidal anti-inflammatory drugs (NSAIDs, e.g. indomethacin), antioxidants, lipid-lowering agents, antihypertensives, selective phosphodiesterase inhibitors, vitamins (E, B12, B6, folic acid) and agents that target neurotransmitter or neuropeptide alterations. Neurotransmitter receptor-based approaches include agents that modulate certain receptors (e.g. nicotinic, muscarinic, α-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid [AMPA], γ-aminobutyric acid [GABA], N-methyl-D-aspartate [NMDA]) and agents that increase the availability of neurotransmitters (e.g. noradrenergic reuptake inhibitors).

Of these strategies, the NMDA receptor antagonist memantine is in the most advanced stage of development in the US and is already approved in Europe as the first treatment for moderately severe to severe Alzheimer’s disease. Memantine is proposed to counteract cellular damage due to pathological activation of NMDA receptors by glutamate. Results with Ginkgo biloba have been mixed. Data for neurotrophic therapies and vitamin E (tocopherol) appear promising but require confirmation. NSAIDs and conjugated estrogens have not proven to be of value to date for the treatment of Alzheimer’s disease. Statins may have a potential role in reducing the risk or delaying the onset of Alzheimer’s disease, although this has yet to be confirmed in randomised trials. There are currently no data to support the use of statins as a treatment for dementia.

This article provides an update on the current status of selected agents, focusing primarily on those agents with the most extensive clinical evidence at present.

Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer’sdisease in the United States and the public health impact ofdelaying disease onset. Am J Public Health 1998 Sep; 88(9): 1337–42PubMedCrossRef

Grutzendler J, Morris JC. Cholinesterase inhibitors for Alzheimer’sdisease. Drugs 2001; 61(1): 41–52PubMedCrossRef

Rocca P, Cocuzza E, Marchiaro L, et al. Donepezil in the treatment of Alzheimer’s disease: long-term efficacy and safety. Prog Neuropsychopharmacol Biol Psychiatry 2002 Feb; 26(2): 369–73PubMedCrossRef

Wilkinson D, Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 2001 Sep; 16(9): 852–7PubMedCrossRef

Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001 Aug 14; 57(3): 489–95PubMedCrossRef

Birks J, Grimley Evans J, Iakovidou V, et al. Rivastigmine for Alzheimer’s disease. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 4. Oxford: Update Software, 1997: CD001191

Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer’s disease. Neurology 1998 May; 50(5): 1222–30PubMedCrossRef

McLendon BM, Doraiswamy PM. Defining meaningful change in Alzheimer’s disease trials: the donepezil experience. J Geriatr Psychiatry Neurol 1999 Spring; 12(1): 39–48PubMedCrossRef

Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001 Aug 14; 57(3): 481–8PubMedCrossRef

10.

Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001 Aug 28; 57(4): 613–20PubMedCrossRef

11.

Muir JL. Acetylcholine, aging, and Alzheimer’s disease. Pharmacol Biochem Behav 1997 Apr; 56(4): 687–96PubMedCrossRef

12.

Olney JW, Wozniak DF, Farber NB. Excitotoxic neurodegeneration in Alzheimer disease: new hypothesis and new therapeutic strategies. Arch Neurol 1997 Oct; 54(10): 1234–40PubMedCrossRef

13.

Emilien G, Beyreuther K, Masters CL, et al. Prospects for pharmacological intervention in Alzheimer disease. Arch Neurol 2000 Apr; 57(4): 454–9PubMedCrossRef

14.

Krieglstein J, Lippert K, Poch G. Apparent independent action of nimodipine and glutamate antagonists to protect cultured neurons against glutamate-induced damage. Neuropharmacology 1996; 35(12): 1737–42PubMedCrossRef

15.

Watkins JC, Evans RH. Excitatory amino acid transmitters. Annu Rev Pharmacol Toxicol 1981; 21: 165–204PubMedCrossRef

16.

Greenamyre JT, Maragos WF, Albin RL, et al. Glutamate transmission and toxicity in Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12(4): 421–30PubMedCrossRef

17.

Arias C, Arrieta I, Tapia R. Beta-amyloid peptide fragment 25–35 potentiates the calcium-dependent release of excitatory amino acids from depolarized hippocampal slices. J Neurosci Res 1995 Jul 1; 41(4): 561–6PubMedCrossRef

18.

Goodwin JL, Uemura E, Cunnick JE. Microglial release of nitric oxide by the synergistic action of beta-amyloid and IFN-gamma. Brain Res 1995 Sep 18; 692(1–2): 207–14PubMedCrossRef

19.

Lees GJ. Contributory mechanisms in the causation of neurodegenerative disorders. Neuroscience 1993 May; 54(2): 287–322PubMedCrossRef

20.

Harris ME, Wang Y, Pedigo Jr NW, et al. Amyloid beta peptide (25–35) inhibits Na+-dependent glutamate uptake in rat hippocampal astrocyte cultures. J Neurochem 1996 Jul; 67(1): 277–86PubMedCrossRef

21.

Liang Z, Valla J, Sefidvash-Hockley S, et al. Effects of estrogen treatment on glutamate uptake in cultured human astrocytes derived from cortex of Alzheimer’s disease patients. J Neurochem 2002 Mar; 80(5): 807–14PubMedCrossRef

22.

Topper R, Gehrmann J, Banati R, et al. Rapid appearance of beta-amyloid precursor protein immunoreactivity in glial cells following excitotoxic brain injury. Acta Neuropathol (Berl) 1995; 89(1): 23–8CrossRef

23.

Chen HS, Pellegrini JW, Aggarwal SK, et al. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 1992 Nov; 12(11): 4427–36PubMed

24.

Wenk GL, Danysz W, Mobley SL. MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur J Pharmacol 1995 Oct 6; 293(3): 267–70PubMedCrossRef

25.

Wenk GL, Danysz W, Mobley SL. Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat. Brain Res 1994 Aug 29; 655(1–2): 7–11PubMedCrossRef

26.

Headley PM, Grillner S. Excitatory amino acids and synaptic transmission: the evidence for a physiological function. Trends Pharmacol Sei 1990 May; 11(5): 205–11CrossRef

27.

Misztal M, Frankiewicz T, Parsons CG, et al. Learning deficits induced by chronic intraventricular infusion of quinolinic acid: protection by MK-801 and memantine. Eur J Pharmacol 1996 Jan 18; 296(1): 1–8PubMedCrossRef

28.

Kornhuber J, Weiler M. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 1997 Jan 15; 41(2): 135–44PubMedCrossRef

29.

Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacology 1999 Jun; 38(6): 735–67PubMedCrossRef

30.

Seif el Nasr M, Peruche B, Rossberg C, et al. Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur J Pharmacol 1990 Aug 21; 185(1): 19–24PubMedCrossRef

31.

Parsons CG, Danysz W, Bartmann A, et al. Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization. Neuropharmacology 1999 Jan; 38(1): 85–108PubMedCrossRef

32.

Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, et al. Memantine prevents beta-amyloid-induced neurotoxicity and learning impairment in rats [abstract]. Neurobiol Aging 2002; 23: S102

33.

Danysz W, Möbius H–J, Parsons CG, et al. Memantine provides neuroprotection in animal models at therapeutically relevant doses [abstract]. Am J Geriatr Psychiatry 2002; 10(2 Suppl. 1): 1–122

34.

Danysz W, Parsons CG, Möbius HJ, et al. Neuroprotective and symptomatological action of memantine relevant for Alzheimer’s disease: a unified glutamatergic hypothesis on the mechanism of action. Neurotox Res 2000; 2: 85–97PubMedCrossRef

35.

Reisberg B, Stöffler A, Ferris S, et al. A placebo-controlled study of memantine in advanced Alzheimer’s disease [abstract]. Am J Geriatr Psychiatry 2002; 10(2 Suppl. 1): 1–122

36.

Wimo A, Winblad B, Stöffler A, et al. Effect of long-term treatment with memantine, an NMDA antagonist, on costs associated with advanced Alzheimer’s disease: results of a 28-week, randomized, double-blind, placebo-controlled study [abstract]. Neurobiol Aging 2002; 23: S44

37.

Reisberg B, Ferris S, Möbius HJ, et al. Long-term treatment with the NMDA antagonist memantine: results of a 24-week, open-label extension study in moderately severe-to-severeAlzheimer’s disease [abstract]. Neurobiol Aging 2002; 23: S555CrossRef

38.

Galasko D. New approaches to diagnose and treat Alzheimer’s disease: a glimpse of the future. Clin Geriatr Med 2001 May; 17(2): 393–410PubMedCrossRef

39.

Teunissen CE, de Vente J, Steinbusch HW, et al. Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid. Neurobiol Aging 2002 Jul–Aug; 23(4): 485–508PubMedCrossRef

40.

Rich JB, Rasmusson DX, Folstein MF, et al. Nonsteroidal anti-inflammatory drugs in Alzheimer’s disease. Neurology 1995 Jan; 45(1): 51–5PubMedCrossRef

41.

Doraiswamy PM, Bieber F, Kaiser L, et al. The Alzheimer’sDisease Assessment Scale: patterns and predictors of baselinecognitive performance in multicenter Alzheimer’s disease trials.Neurology 1997 Jun; 48(6): 1511–7PubMedCrossRef

42.

Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial ofindomethacin in Alzheimer’s disease. Neurology 1993 Aug;43(8): 1609–11PubMedCrossRef

43.

Scharf S, Mander A, Ugoni A, et al. A double-blind, placebo-controlledtrial of diclofenac/misoprostol in Alzheimer’s disease.Neurology 1999 Jul 13; 53(1): 197–201PubMedCrossRef

44.

Sainati SM, Ingram DM, Talwalker S, et al. Results of a double-blind,randomized, placebo-controlled study of celecoxib inthe treatment of progression of Alzheimer’s disease. 6th InternationalStockholm/Springfield Meeting on Advances inAlzheimer Therapy; 2000 Apr 5–8; Stockholm, Sweden

45.

Aisen P, Schafer K, Grundman M, et al. Results of a multicentertrial of rofecoxib and naproxen in Alzheimer’s disease [abstract].Neurobiol Aging 2002; 23: S429

46.

Block G, Norman B, Liu G, et al. A clinical trial of rofecoxib,a selective COX-2 inhibitor, for the treatment of Alzheimer’sdisease [abstract]. Neurobiol Aging 2002; 23: S73

47.

in t’Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidalantiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 2001 Nov 22; 345(21): 1515–21CrossRef

48.

Breteler MM, in t’Veld BA, Hofman A, et al. A beta-42 peptidelowering NSAIDs and Alzheimer’s disease. Neurobiol Aging2002; 23: S286

49.

Wolfson C, Perrault A, Moride Y, et al. A case-control analysisof nonsteroidal anti-inflammatory drugs and Alzheimer’s disease:are they protective? Neuroepidemiology 2002 Mar–Apr;21(2): 81–6PubMedCrossRef

50.

Stewart WF, Kawas C, Corrada M, et al. Risk of Alzheimer’sdisease and duration of NSAID use. Neurology 1997 Mar; 48(3): 626–32PubMedCrossRef

51.

Anthony JC, Breitner JC, Zandi PP, et al. Reduced prevalenceof AD in users of NSAIDs and H2 receptor antagonists: theCache County study. Neurology 2000 Jun 13; 54(11): 2066–71PubMedCrossRef

52.

Breitner JC, Zandi PP. Do nonsteroidal antiinflammatory drugsreduce the risk of Alzheimer’s disease? N Engl J Med 2001Nov 22; 345(21): 1567–8PubMedCrossRef

53.

Beal MF. Aging, energy, and oxidative stress in neurodegenerativediseases. Ann Neurol 1995 Sep; 38(3): 357–66PubMedCrossRef

54.

Benzi G, Moretti A. Are reactive oxygen species involved inAlzheimer’s disease? Neurobiol Aging 1995 Jul–Aug; 16(4):661–74PubMedCrossRef

55.

McGeer PL, McGeer EG. The inflammatory response system ofbrain: implications for therapy of Alzheimer and other neurodegenerativediseases. Brain Res Brain Res Rev 1995 Sep; 21(2): 195–218PubMedCrossRef

56.

McGeer PL, McGeer EG. Anti-inflammatory drugs in the fightagainst Alzheimer’s disease. Ann N Y Acad Sci 1996 Jan 17;777: 213–20PubMedCrossRef

57.

Oken BS, Storzbach DM, Kaye JA. The efficacy of ginkgobiloba on cognitive function in Alzheimer disease. Arch Neurol 1998 Nov; 55(11): 1409–15PubMedCrossRef

58.

Wettstein A. Cholinesterase inhibitors and gingko extracts: arethey comparable in the treatment of dementia? Comparisonof published placebo-controlled efficacy studies of at least sixmonths’ duration. Phytomedicine 2000 Jan; 6(6): 393–401PubMedCrossRef

59.

van Dongen MC, van Rossum E, Kessels AG, et al. The efficacyof ginkgo for elderly people with dementia and age-associatedmemory impairment: new results of a randomized clinicaltrial. J Am Geriatr Soc 2000 Oct; 48(10): 1183–94PubMed

60.

Schreiter Gasser U, Gasser T. A comparison of cholinesteraseinhibitors and ginkgo extract in treatment of Alzheimer dementia.Fortschr Med Orig 2001 Nov 29; 119(3–4): 135–8

61.

Stough C, Clarke J, Lloyd J, et al. Neuropsychological changesafter 30-day ginkgo biloba administration in healthy participants.Int J Neuropsychopharmacol 2001 Jun; 4(2): 131–4

62.

Solomon PR, Adams F, Silver A, et al. Ginkgo for memoryenhancement: a randomized controlled trial. JAMA 2002 Aug 21; 288(7): 835–40PubMedCrossRef

63.

Tuszynski MH, Sang H, Yoshida K, et al. Recombinant humannerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann Neurol 1991 Nov; 30(5): 625–36PubMedCrossRef

64.

Olson L. NGF and the treatment of Alzheimer’s disease. ExpNeurol 1993 Nov; 124(1): 5–15

65.

Ringheim GE. Glial modulating and neurotrophic properties ofpropentofylline and its application to Alzheimer’s disease andvascular dementia. Ann N Y Acad Sci 2000 Apr; 903: 529–34PubMedCrossRef

66.

Shimazu S, Tachikawa N, Iwamoto N, et al. The neurotrophic action and brain protective effect of cerebrolysin [abstract]. Neurobiol Aging 1992; 13 Suppl. 1: S50

67.

Albrecht E, Hingel S, Crailsheim K, et al. The effects of cerebrolysin on survival and sprouting of neurons from cerebral hemispheres and from the brain stem of chicken embryos in vitro [abstract]. Neurobiol Aging 1992; 13 Suppl. 1: S127CrossRef

68.

Bae CY, Cho CY, Cho K, et al. A double-blind, placebo-controlled, multicenter study of cerebrolysin for Alzheimer’s disease. J Am Geriatr Soc 2000 Dec; 48(12): 1566–71PubMed

69.

Ruther E, Ritter R, Apecechea M, et al. Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). Pharmacopsychiatry 1994 Jan; 27(1): 32–40PubMedCrossRef

70.

Ruther E, Ritter R, Apecechea M, et al. Sustained improvements in patients with dementia of Alzheimer’s type (DAT) 6 months after termination of cerebrolysin therapy. J Neural Transm 2000; 107(7): 815–29PubMedCrossRef

71.

Panisset M, Gauthier S, Moessler H, et al. Cerebrolysin in Alzheimer’s disease: a randomized, double-blind, placebocontrolled trial with a neurotrophic agent. J Neural Transm 2002 Jul; 109(7–8): 1089–104PubMedCrossRef

72.

Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease: Donepezil Study Group. Neurology 1998 Jan; 50(1): 136–45PubMedCrossRef

73.

Rainer M, Mucke HA, Kruger-Rainer C, et al. Cognitive relapse after discontinuation of drug therapy in Alzheimer’s disease: cholinesterase inhibitors versus nootropics. J Neural Transm 2001; 108(11): 1327–33PubMedCrossRef

74.

Refolo LM, Malester B, LaFrancois J, et al. Hypercholesterolemiaaccelerates the Alzheimer’s amyloid pathology in a transgenicmouse model. Neurobiol Dis 2000 Aug; 7(4): 321–31PubMedCrossRef

75.

Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia.Lancet 2000 Nov 11; 356(9242): 1627–31PubMedCrossRef

76.

Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalenceof Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000 Oct; 57(10): 1439–43PubMedCrossRef

77.

Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002 Feb; 59(2): 223–7PubMedCrossRef

78.

Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer’s disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A 2001 May 8; 98(10): 5856–61PubMedCrossRef

79.

Sterzer P, Meintzschel F, Rosler A, et al. Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease. Stroke 2001 Dec 1; 32(12): 2817–20PubMedCrossRef

80.

Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy 2001 Jun; 21(6): 767–9PubMedCrossRef

81.

Barrett AM. Probable Alzheimer’s disease: gender-related issues. J Gend Specif Med 1999 Jan–Feb; 2(1): 55–60PubMed

82.

Luine VN. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol 1985 Aug; 89(2): 484–90PubMedCrossRef

83.

Toran-Allerand CD, Miranda RC, Bentham WD, et al. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci U S A 1992 May 15; 89(10): 4668–72PubMedCrossRef

84.

Henderson VW. Estrogen, cognition, and a woman’s risk of Alzheimer’s disease. Am J Med 1997 Sep 22; 103(3A): 11S–8SPubMedCrossRef

85.

Birge SJ. The role of estrogen in the treatment and prevention of dementia: introduction. Am J Med 1997 Sep 22; 103(3A): 1S–2SPubMedCrossRef

86.

Asthana S, Craft S, Baker LD, et al. Cognitive and neuroendocrineresponse to transdermal estrogen in postmenopausal womenwith Alzheimer’s disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology 1999 Aug; 24(6): 657–77PubMedCrossRef

87.

Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology 2000 Jun 13; 54(11): 2061–6PubMedCrossRef

88.

Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer’s disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000 Jan 25; 54(2): 295–301PubMedCrossRef

89.

Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial: Alzheimer’s Disease Cooperative Study. JAMA 2000 Feb 23; 283(8): 1007–15PubMedCrossRef

90.

Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer’s disease in women. Am J Epidemiol 1994 Aug 1; 140(3): 256–61PubMed

91.

Henderson VW, Paganini-Hill A, Emanuel CK, et al. Estrogen replacement therapy in older women: comparisons between Alzheimer’s disease cases and nondemented control subjects. Arch Neurol 1994 Sep; 51(9): 896–900PubMedCrossRef

92.

Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen duringmenopause on risk and age at onset of Alzheimer’s disease. Lancet 1996 Aug 17; 348(9025): 429–32PubMedCrossRef

93.

Baldereschi M, Di Carlo A, Lepore V, et al. Estrogen-replacementtherapy and Alzheimer’s disease in the Italian Longitudinal Study on Aging. Neurology 1998 Apr; 50(4): 996–1002PubMedCrossRef

94.

Writing Group for the Women’s Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002 Jul 17; 288(3): 321–33CrossRef

95.

Markesbery WR, Carney JM. Oxidative alterations in Alzheimer’s disease. Brain Pathol 1999 Jan; 9(1): 133–46PubMedCrossRef

96.

McCaddon A, Davies G, Hudson P, et al. Total serum homocysteinein senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998 Apr; 13(4): 235–9PubMedCrossRef

97.

Lehmann M, Gottfries CG, Regland B. Identification of cognitiveimpairment in the elderly: homocysteine is an early marker. Dement Geriatr Cogn Disord 1999 Jan–Feb; 10(1): 12–20PubMedCrossRef

98.

Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 2002 Feb 14; 346(7): 476–83PubMedCrossRef

99.

Paleologos M, Cumming RG, Lazarus R. Cohort study of vitamin C intake and cognitive impairment. Am J Epidemiol 1998 Jul 1; 148(1): 45–50PubMedCrossRef

100.

Morris MC, Beckett LA, Scherr PA, et al. Vitamin E and vitaminC supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 1998 Sep; 12(3): 121–6PubMedCrossRef

101.

Sano M, Ernesto C, Thomas RG, et al. A controlled trial ofselegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease: the Alzheimer’s Disease Cooperative Study. N Engl J Med 1997 Apr 24; 336(17): 1216–22PubMedCrossRef

102.

Schenk D, Barbour R, Dunn W, et al. Immunization with amyloidbetaattenuates Alzheimer-disease-like pathology in the PDAPPmouse. Nature 1999 Jul 8; 400(6740): 173–7PubMedCrossRef

103.

Elan Corporation & Wyeth-Ayerst Laboratories, 2002. (Data onfile)

104.

Lee JY, Mook-Jung I, Koh JY. Histochemically reactive zincin plaques of the Swedish mutant beta-amyloid precursor protein transgenic mice. J Neurosci 1999 Jun 1; 19(11): RC10PubMed

105.

Smith MA, Harris PL, Sayre LM, et al. Iron accumulation inAlzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A 1997 Sep 2; 94(18): 9866–8PubMedCrossRef

106.

Lovell MA, Robertson JD, Teesdale WJ, et al. Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci 1998 Jun 11; 158(1): 47–52PubMedCrossRef

107.

Suh SW, Jensen KB, Jensen MS, et al. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer’s diseased brains. Brain Res 2000 Jan 10; 852(2): 274–8PubMedCrossRef

108.

Cherny RA, Legg JT, McLean CA, et al. Aqueous dissolution of Alzheimer’s disease Abeta amyloid deposits by biometal depletion. J Biol Chem 1999 Aug 13; 274(33): 23223–8PubMedCrossRef

109.

Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron 2001 Jun; 30(3): 665–76PubMedCrossRef

110.

Regland B, Lehmann W, Abedini I, et al. Treatment of Alzheimer’sdisease with clioquinol. Dement Geriatr Cogn Disord 2001 Nov–Dec; 12(6): 408–14PubMedCrossRef

111.

Prama Biotechnology, 2002. (Data on file)

112.

Gualtieri F, Manetti D, Romanelli MN, et al. Design and studyof piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs. Curr Pharm Des 2002; 8(2): 125–38PubMedCrossRef

113.

Danysz W, Parsons CG, Quack G. NMDA channel blockers: memantine and amino-aklylcyclohexanes: in vivo characterization. Amino Acids 2000; 19(1): 167–72PubMedCrossRef

114.

Hoerr R, Noeldner M. Ensaculin (KA-672 HC1): a multi-transmitter approach to dementia treatment. CNS Drug Rev 2002 Sum; 8(2): 143–58PubMedCrossRef

115.

Schneider LS, Farlow MR, Henderson VW, et al. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer’s disease. Neurology 1996 Jun; 46(6): 1580–4PubMedCrossRef

Titel: Non-Cholinergic Strategies for Treating and Preventing Alzheimer’s Disease
verfasst von: Dr P. Murali Doraiswamy
Publikationsdatum: 01.12.2002
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 12/2002
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200216120-00003

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen